Patents by Inventor Andres Tover

Andres Tover has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Human papilloma virus replication inhibitors
    Patent number: 11000529
    Abstract: Methods for treating high risk HPV infection by inhibiting one or more phases of HPV replication cycle with antiviral compounds are disclosed. Moreover, a mechanism for the inhibition is suggested and targets for further antiviral compounds are disclosed.
    Type: Grant
    Filed: September 12, 2019
    Date of Patent: May 11, 2021
    Assignee: Icosagen Cell Factory OÜ
    Inventors: Mart Ustav, Sr., Ene Ustav, Andres Männik, Mart Toots, Andres Tover
  • Assay system to identify HPV replication inhibitors in HT-screen
    Patent number: 10954545
    Abstract: A U2OS-based model system using luciferase reporters to monitor the genome replication of alpha and beta HPVs is provided. A modified U2OS cell line is disclosed that expresses Firefly luciferase to measure toxicity of the screened compounds. In addition, provided are HPV18, HPV 16 and HPV5 marker genomes that express Renilla luciferase under the control of viral promoters used to measure changes in the viral copy number. This ready-to-use model system is capable of being used in high-throughput screens to identify compounds inhibiting initial amplification and stable maintenance as well as vegetative phase of various HPV subtypes.
    Type: Grant
    Filed: April 11, 2016
    Date of Patent: March 23, 2021
    Assignee: Icosagen Cell Factory OÜ
    Inventors: Mart Ustav, Ene Ustav, Andres Männik, Mart Toots, Mart Ustav, Jr., Andres Tover
  • Human papilloma virus replication inhibitors
    Publication number: 20200046730
    Abstract: Methods for treating high risk HPV infection by inhibiting one or more phases of HPV replication cycle with antiviral compounds are disclosed. Moreover, a mechanism for the inhibition is suggested and targets for further antiviral compounds are disclosed.
    Type: Application
    Filed: September 12, 2019
    Publication date: February 13, 2020
    Applicant: Icosagen Cell Factory OÜ
    Inventors: Mart USTAV, SR., Ene USTAV, Andres MÄNNIK, Mart TOOTS, Andres TOVER
  • Human papilloma virus replication inhibitors
    Patent number: 10543218
    Abstract: Novel antiviral compounds for inhibiting one or more phases of HPV replication cycle are disclosed. Moreover, a mechanism for the inhibition is suggested and targets for further antiviral compounds are disclosed.
    Type: Grant
    Filed: May 11, 2016
    Date of Patent: January 28, 2020
    Assignee: Icosagen Cell Factory OÜ
    Inventors: Mart Ustav, Sr., Ene Ustav, Andres Männik, Mart Toots, Andres Tover
  • Assay system to identify HPV replication inhibitors in HT-screen
    Publication number: 20180155756
    Abstract: A U2OS-based model system using luciferase reporters to monitor the genome replication of alpha and beta HPVs is provided. A modified U2OS cell line is disclosed that expresses Firefly luciferase to measure toxicity of the screened compounds. In addition, provided are HPV18, HPV 16 and HPV5 marker genomes that express Renilla luciferase under the control of viral promoters used to measure changes in the viral copy number. This ready-to-use model system is capable of being used in high-throughput screens to identify compounds inhibiting initial amplification and stable maintenance as well as vegetative phase of various HPV subtypes.
    Type: Application
    Filed: April 11, 2016
    Publication date: June 7, 2018
    Applicant: Icosagen Cell Factory OÜ
    Inventors: Mart USTAV, Ene USTAV, Andres MÄNNIK, Mart TOOTS, Mart USTAV, JR., Andres TOVER
  • Human papilloma virus replication inhibitors
    Publication number: 20180133228
    Abstract: Novel antiviral compounds for inhibiting one or more phases of HPV replication cycle are disclosed. Moreover, a mechanism for the inhibition is suggested and targets for further antiviral compounds are disclosed.
    Type: Application
    Filed: May 11, 2016
    Publication date: May 17, 2018
    Applicant: Icosagen Cell Factory OÜ
    Inventors: Mart Ustav, Sr., Ene Ustav, Andres Männik, Mart Toots, Andres Tover
  • Viral expression plasmids for production of proteins, antibodies, enzymes, virus-like particles and for use in cell-based assays
    Publication number: 20130236958
    Abstract: This disclosure shows that the EBV FR-element comprised of EBNA1 multimeric binding sites can provide the stable maintenance replication function to the mouse polyomavirus (PyV) core origin plasmids in the presence of BPV-1 E2 protein and PyV large T-antigen (LT).
    Type: Application
    Filed: January 23, 2013
    Publication date: September 12, 2013
    Applicant: ICOSAGEN CELL FACTORY OU
    Inventors: Toomas SILLA, Ingrid TAGEN, Jelizaveta GEIMANEN, Kadri JANIKSON, Aare ABROI, Ene USTAV, Mart USTAV, Tiiu MANDEL, Urve TOOTS, Andres TOVER, Anne KALLING, Radi TEGOVA
  • Viral expression plasmids for production of proteins, antibodies, enzymes, virus-like particles and for use in cell-based assays
    Patent number: 8377653
    Abstract: This disclosure shows that the EBV FR-element comprised of EBNA1 multimeric binding sites can provide the stable maintenance replication function to the mouse polyomavirus (PyV) core origin plasmids in the presence of BPV-1 E2 protein and PyV large T-antigen (LT).
    Type: Grant
    Filed: July 7, 2010
    Date of Patent: February 19, 2013
    Assignee: Icosagen Cell Factory Oü
    Inventors: Toomas Silla, Ingrid Tagen, Anne Kalling, Radi Tegova, Mart Ustav, Tiiu Mandel, Urve Toots, Andres Tover, Aare Abroi, Ene Ustav, Jelizaveta Geimanen, Kadri Janikson
  • Viral expression plasmids for production of proteins, antibodies, enzymes, virus-like particles and for use in cell-based assays
    Publication number: 20110076760
    Abstract: This disclosure shows that the EBV FR-element comprised of EBNA1 multimeric binding sites can provide the stable maintenance replication function to the mouse polyomavirus (PyV) core origin plasmids in the presence of BPV-1 E2 protein and PyV large T-antigen (LT).
    Type: Application
    Filed: July 7, 2010
    Publication date: March 31, 2011
    Applicant: Icosagen S.A.
    Inventors: Toomas Silla, Ingrid Tagen, Anne Kalling, Radi Tegova, Mart Ustav, Tiiu Mandel, Urve Toots, Andres Tover, Aare Abroi, Ene Ustav, Jelizaveta Geimanen, Kadri Janikson